Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11
May 04 2023 - 8:00AM
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene
therapy company focused on developing and commercializing AAV-based
gene therapies for the treatment of monogenic diseases of the
central nervous system (CNS), today announced that it will report
its financial results for the first quarter ended March 31, 2023,
and host a corporate update conference call and webcast on
Thursday, May 11, 2023, at 4:30 PM Eastern Time.
Conference Call
Details |
Thursday, May 11,
at 4:30 PM Eastern Time / 3:30 PM Central
Time |
Toll Free: 855-327-6837 |
International:
631-891-4304 |
Conference ID: 10021767 |
https://ir.tayshagtx.com/news-events/events-presentations |
|
About Taysha Gene
Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program. Together, we leverage our fully integrated platform with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
Company Contact:Hayleigh CollinsDirector, Head
of Corporate CommunicationsTaysha Gene
Therapieshcollins@tayshagtx.com
Media Contact:Carolyn HawleyCanale
Communications carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jul 2023 to Jul 2024